"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 2 | 4 | 6 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 4 | 5 |
| 2006 | 2 | 2 | 4 |
| 2007 | 5 | 0 | 5 |
| 2008 | 3 | 2 | 5 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 3 | 5 |
| 2011 | 0 | 3 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 4 | 0 | 4 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 6 | 2 | 8 |
| 2023 | 0 | 1 | 1 |
| 2024 | 3 | 1 | 4 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Treverton J, Arnold DM, Ivanov DG, Ivetic N, Zhang Y, Ali HA, Clare R, Kaltashov IA, Kelton JG, Nazy I. Monoclonal Antibodies in the Pathogenesis of Heparin-Induced Thrombocytopenia. N Engl J Med. 2025 Sep 04; 393(9):879-886.
-
Du Y, Yang Y, Nguyen SN, Kaltashov IA. The Role of Long-Range Non-Specific Electrostatic Interactions in Inhibiting the Pre-Fusion Proteolytic Processing of the SARS-CoV-2 S Glycoprotein by Heparin. Biomolecules. 2025 May 28; 15(6).
-
Stubblefield WB, Helderman R, Strokes N, Greineder CF, Barnes GD, Vinson DR, Westafer LM. Factors in Initial Anticoagulation Choice in Hospitalized Patients With Pulmonary Embolism. JAMA Netw Open. 2025 01 02; 8(1):e2452877.
-
Westafer LM, Presti T, Shieh MS, Pekow PS, Barnes GD, Kapoor A, Lindenauer PK. Trends in Initial Anticoagulation Among US Patients Hospitalized With Acute Pulmonary Embolism 2011-2020. Ann Emerg Med. 2024 Nov; 84(5):518-529.
-
King RM, Peker A, Epshtein M, Arends JM, Brochu AB, Raskett CM, Slazas KJ, Puri AS, Arthur AS, Fiorella D, Gounis MJ, Anagnostakou V. Active drug-coated flow diverter in a preclinical model of intracranial stenting. J Neurointerv Surg. 2024 Jun 17; 16(7):731-736.
-
Sukumaran M, Cantrell DR, D'Agostino C, Jahromi BS, Ansari SA, Potts MB. Bivalirudin as a substitute for heparin in neurointervention for patients with heparin-induced thrombocytopenia. J Stroke Cerebrovasc Dis. 2024 Jun; 33(6):107310.
-
Yang Y, Du Y, Ivanov D, Niu C, Clare R, Smith JW, Nazy I, Kaltashov IA. Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4. Commun Biol. 2024 03 11; 7(1):308.
-
Habibi S, Hsieh TC, Khanna S. Perioperative Plasma Exchange and Intravenous Immunoglobulin Use for Refractory Heparin-Induced Thrombocytopenia in a Liver Transplant Recipient. Am J Case Rep. 2023 Dec 30; 24:e941865.
-
Lawlor M, Gupta A, Ranard LS, Madhavan MV, Li J, Eisenberger A, Parikh SA, Sethi SS, Masoumi A. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.
-
Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, Schmidt CM, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. J Am Coll Surg. 2021 01; 232(1):91-100.